---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-275336"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:25:50.220365+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Silverback Therapeutics announces final exchange ratio of 1.1819 for merger with ARS Pharma

## Summary
- Final exchange ratio set at 1.1819 per the Merger Agreement as amended on October 25, 2022.
- Merger with ARS Pharmaceuticals remains subject to stockholder approval and other closing conditions.
- Shareholders are urged to read the definitive proxy statement filed on October 6, 2022.

## SEC filing metadata
- accession: 0001193125-22-275336
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312522275336/0001193125-22-275336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312522275336/d408267d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-275336
- JSON: https://secwatch.observer/filing/0001193125-22-275336.json
- Plain text: https://secwatch.observer/filing/0001193125-22-275336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.